Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
72 Results Found
AHA files amicus brief in 4th Circuit in support of Maryland 340B contract pharmacy law
The AHA Feb.
RFID Solutions Attract Attention for Medication Inventory Management
More organizations are giving radio frequency identification (RFID) systems a second look to aid in medication management accuracy, safety and efficiency.
Fact Sheet: 340B Drug Pricing Program Contract Pharmacy Arrangements
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for patients in vulnerable communities.
AHA Urges Administration to Grant Exceptions for Tariffs for Medications and Medical Supplies
The AHA asks President Trump to consider granting exceptions to the current and proposed tariffs for medical devices and pharmaceuticals made in Mexico, Canada and China that are essential to the provision of safe, effective care in America's hospitals, clinics, and other settings.
Senate introduces bill requiring price disclosures on ads for prescription drugs
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that would require price disclosures on advertisements for prescription drugs. The bill would help ensure that consumers are able to make more informed decisions on prescription drugs.
HHS announces next 15 drugs selected for price negotiations
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations.
Report: Prices for top Medicare Part D drugs nearly doubled since entering the market
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by the AARP Public Policy Institute.
Research finds drug prices increased without adding new clinical benefits
The net prices of five drugs included in a new study from the Institute for Clinical and Ec
AHA responds to Medicare $2 Drug List Model request for information
The AHA supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs for a low, fixed copayment no higher than $2 for a month’s supply per drug.
AHA Comments on CMS Proposed Medicare Drug Pricing Model
AHA comments regarding the Centers for Medicare & Medicaid Services Medicare $2 Drug List (M2DL) Model request for information (RFI).